Full Press Release Details
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49.
ZYME
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
Key Takeaway: Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers